Search

Cord Blood Connect 2025 Tracks

Discover what’s ahead in the Scientific and Technical Tracks at Cord Blood Connect 2025!

Scientific Track

Session 1: Cord Blood Transplantation: Clinical Outcomes and New Strategies

This session will focus on the latest advancements in the field of umbilical cord blood transplantation (CBT). The session will bring together international experts to discuss clinical outcomes and emerging strategies that enhance the utilization of cord blood in hematopoietic stem cell transplantation. 

Key topics will include: 

  • Clinical Outcomes Across Different Regions: Experts from various countries will share real-world data on survival rates, engraftment success, and long-term patient outcomes, highlighting regional variations and best practices. 
  • Innovative Strategies to Improve Cord Blood Utilization: Presentations will cover advancements such as ex vivo expansion, double-unit transplants, immune modulation techniques, and novel conditioning regimens. 

By featuring a global perspective, this session aims to foster collaboration, share lessons learned, and explore the future of cord blood transplantation as a viable alternative donor source worldwide. 

Session 2: Cord Blood and its Unique Biological Aspects 

This session will explore the distinct biological properties of CB that make it a valuable resource for transplantation and regenerative medicine. Experts will discuss the unique cellular composition, immunological advantages, and emerging research on cord blood’s therapeutic potential. 

By examining what sets cord blood apart, this session will highlight its expanding role in transplantation, immunotherapy, and regenerative medicine. 

Session 3: Cord Blood for Regenerative Medicine 

This session at Cord Blood Connect will focus on the expanding role of umbilical CB in regenerative medicine, highlighting its potential beyond hematopoietic stem cell transplantation. Experts will discuss cutting-edge research, clinical applications, and future directions for using cord blood-derived cells in treating a wide range of diseases. 

Key topics will include: 

  • Current and Emerging Clinical Applications 
  • Mechanisms of Tissue Repair and Regeneration 
  • Challenges and Opportunities in Translational Research: Advances in cell expansion, banking strategies, and regulatory considerations for bringing cord blood-based regenerative therapies to clinical practice. 

This session will provide a global perspective on the future of cord blood in regenerative medicine, emphasizing scientific progress, clinical evidence, and pathways to broader adoption. 

Session 4: Lightning Talks – The Future of Cord Blood: Bold Visions and Innovations 

This engaging and forward-thinking session at Cord Blood Connect will feature short, powerful presentations designed to educate, inspire and spark meaningful conversation. These short presentations will be delivered by visionary experts across the globe, sharing their ideas for the future of cord blood and birthing tissue. Speakers will present bold ideas on how cord blood can transform medicine, push scientific boundaries, and expand its impact in both transplantation and regenerative therapies. 

Key themes will include: 

  • Next-Generation Applications: How cord blood could revolutionize treatments for cancer, autoimmune diseases, neurodegenerative disorders, and beyond. 
  • Technological Innovations: The role of AI, gene editing, and cell engineering in enhancing the potential of cord blood-derived therapies. 

  • Global Accessibility and Policy Evolution: Strategies to make cord blood banking and therapies more widely available across diverse populations. 

This session aims to inspire new ideas, spark discussions, and challenge conventional thinking about where cord blood could go in the next years. 

Technical Track

How do we grow our cord blood industry?

The key objective of this year’s Cord Blood Connect technical track is to bring international experts from diverse backgrounds to discuss the growth challenges of the cord blood industry globally.  

Session 1: Role of MSCs in the Development of Regenerative Cell Therapies

How we can expand the scope of our sector evolving from a cord blood transplantation focus to a birthing tissue cell therapy approach, expanding the main interest from transplant medicine to other specialties such as pediatrics, endocrinology, neurology, among others.  

Key topics will include: 

  • Cord tissue MSC clinical trials in auto immune diseases 
  • Placenta derived MSC applications 

  • Where and for what have birthing tissue stem cells been approved for clinical use? 

Session 2: Communication and Awareness Challenge 

Raising the awareness of families and doctors by balancing modern marketing techniques with good scientific evidence has also been an area of opportunity to achieve sustainable long-term growth in our sector.  

Key topics will include: 

  • How is the informed-consent process contributing, or not? 
  • Where do we draw the line between marketing and ethics? 

  • What is the position of ob/gyn's and pediatricians? 

Session 3: Key Scaling and Growth Challenges 

Addressing the challenge of scaling the Cord blood industry is critical for increasing the impact of our work.

Key topics will include:  

  • What lessons have we learned from recent industry consolidations around the world? 
  • How to grow faster with quality? Are medical/scientific excellence, and acquiring sustainable profitability, conflicting objectives?  
  • What new avenues would benefit from years of professional expertise in other areas like genetic testing and biobanking?
  • What role should public banking play going forward? 

Session 4: Global Perspective & Regulatory Harmonization 

Bring the global perspective to facilitate the sharing of diverse industry experiences and regulatory frameworks across the globe and how effective different regions have been in fostering healthy growth.  

Key topics will include: 

  • How and why do China, Japan and India differ so substantially from US, Europe and Latin America, in terms of the industry’s characteristics?
  • Is global regulatory harmonization wishful thinking or a feasible objective?  

  • How does the regulatory frameworks of China, Japan, US, Europe and Latin America compare, and how can they compliment each other? 

Questions?

Send an email to [email protected].